Shukra Pharmaceuticals Fair Value
Shukra Pharmaceuticals (SHUKRAPHAR) average fair value is ₹35.77 across 4 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF), vs a current market price of ₹55.93 (-36.04%), fair value range ₹0.66–₹63.08. For live price and a broader fundamental view, visit Shukra Pharmaceuticals stock price NSE.
Fair Value Analysis Export
SHUKRAPHAR Fair Value vs Current Price — Valuation Summary
SHUKRAPHAR average fair value, fair value range, price gap and valuation status across 4 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF). Read SHUKRAPHAR dividend track record for the complete payout history and dividend yield track record.
P/B Based Valuation
Dividend Discount Model
Price-to-Sales Valuation
Asset-Based Valuation
Discounted Cash Flow (DCF)
SHUKRAPHAR Fair Value Analysis — Data Sources & Coverage
Shukra Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Browse Shukra Pharmaceuticals financial data for revenue, profit, balance sheet and cash flow data.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
SHUKRAPHAR vs Healthcare Sector Peers — P/E, P/B & Market Cap
Shukra Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.